Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine.

ABSTRACT: Lung cancer is a major malignancy that poses a significant threat to human health, with its complex pathogenesis and molecular characteristics presenting substantial challenges for treatment. Traditional two-dimensional cell cultures and animal models are limited in their ability to accurately replicate the characteristics of different lung cancer patients, thereby hindering research on disease mechanisms and treatment strategies. The development of organoid technology has enabled the growth of patient-derived tumor cells in three-dimensional cultures, which can stably preserve the tumor's tissue morphology, genomic features, and drug response. There have been significant advancements in the field of patient-derived lung cancer organoids (PDLCOs), challenges remain in the reproducibility a

SUBMITTER: Liu C 

PROVIDER: S-EPMC12037501 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature